查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2149017

乾癬性關節炎治療市場規模、佔有率、成長率、全球產業分析、區域趨勢及2026-2034年預測。

Psoriatic Arthritis Treatment Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

乾癬性關節炎治療市場的成長要素

2025年全球乾癬性關節炎治療市場規模為125.9億美元，預計將從2026年的139.7億美元成長至2034年的321.1億美元，預測期內複合年成長率（CAGR）為10.96%。北美地區在2025年將佔市場主導地位，市場佔有率達43.78%，這主要得益於生物製藥的高滲透率、完善的醫療保健基礎設施、廣泛的研發投入以及快速的法規核准流程。

乾癬性關節炎是一種涉及關節和皮膚的慢性自體免疫發炎性疾病，通常與乾癬有關。疾病盛行率上升、公眾意識增強、診斷技術進步、醫療成本上漲以及創新生物製藥的引入，正在推動乾癬性關節炎治療市場的擴張。

市場定義和範圍

乾癬性關節炎治療市場包括用於控制關節發炎、疼痛、皮膚症狀和疾病進展的藥物療法。治療方案包括非類固醇消炎劑（DMARDs）、生物製劑類疾病修飾抗發炎藥（DMARDs）和其他療法。

此外，該市場涵蓋多種給藥途徑（尤其是口服和腸外給藥），並透過醫院藥房、零售藥房、線上藥房和其他分銷管道進行供應。由於標靶生物製藥和生物相似藥的日益普及，市場格局正在進一步擴大。

市場動態

促進因素

乾癬性關節炎盛行率的上升是市場成長的主要促進因素。人口老化、生活壓力大、銀屑病患病率增加、預期壽命延長以及疾病診斷準確率的提高，都促使了患者數量的成長。此外，銀屑病與乾癬性關節炎之間的密切聯繫也增加了對有效治療方法的需求。

另一個關鍵促進因素是強大的創新生物製藥開發平臺。製藥公司正在加大對標靶治療的投資，旨在改善臨床療效。新產品的核准和策略合作正在加速治療創新，並擴大先進療法的可及性。

趨勢

生物製藥的日益普及是一個重要的市場趨勢。除了傳統療法外，針對特定發炎路徑的生物製藥和生物相似藥正發揮日益重要的補充作用。對研發、臨床試驗和先進治療方法投入的增加預計將進一步加速生物製藥的普及應用。

線上藥局和遠端醫療服務的擴張是另一個新趨勢，提高了取得處方箋的便利性，也使長期治療管理更加便捷。

阻礙因素

生物製藥療法的高成本仍然是一個重要的阻礙因素，尤其是在醫療成本和保險覆蓋範圍可能有限的開發中國家。副作用、診斷延遲、治療管理難題、嚴格的監管要求以及專利到期等因素也會影響市場成長。

新冠疫情的影響

新冠疫情影響了傳統醫療保健服務的可近性，需要定期復診的患者面臨許多限制，就診次數也隨之減少。然而，遠端醫療和線上藥局服務的普及使得患者能夠遠距獲得諮詢、處方箋和藥物。儘管人們對免疫抑制療法有擔憂，但由於醫療服務提供者繼續透過替代療法管理乾癬性關節炎患者，疫情對市場的長期影響有限。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇

第4章：主要考慮因素

  • 主要國家和地區乾癬性關節炎的盛行率
  • 近期行業趨勢包括合作、併購和新產品發布。
  • 主要公司的管道分析
  • 各主要國家的法律規範
  • 新冠疫情的影響：乾癬性關節炎治療市場

第5章：2021-2034年全球乾癬性關節炎治療市場分析、洞察與預測

  • 主要發現與總結
  • 市場分析、洞察與預測：按藥物類別分類
    • 非類固醇消炎劑（NSAIDs）
    • 非生物緩解疾病抗風濕藥物
    • 生物製藥（緩解疾病抗風濕藥物）
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 腸外
    • 外用
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥房
    • 網路藥房
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美乾癬性關節炎治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲乾癬性關節炎治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區乾癬性關節炎治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲乾癬性關節炎治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲乾癬性關節炎治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 主要行業趨勢
  • 全球市佔率分析（2025 年）
  • 公司簡介
    • AbbVie Inc.
    • Novartis AG
    • Johnson & Johnson Services, Inc.
    • Pfizer Inc.,
    • LEO Pharma A/S
    • Merck & Co., Inc.
    • Amgen Inc.
    • Eli Lilly and Company
    • CELGENE CORPORATION
    • UCB SA
    • Sun Pharmaceutical Industries Ltd.
    • Other prominent players

第12章 戰略建議

Product Code: FBI101066

Growth Factors of psoriatic arthritis treatment Market

The global psoriatic arthritis treatment market size was valued at USD 12.59 billion in 2025 and is projected to grow from USD 13.97 billion in 2026 to USD 32.11 billion by 2034, exhibiting a CAGR of 10.96% during the forecast period. North America dominated the market with a 43.78% share in 2025, supported by high adoption of biologic therapies, strong healthcare infrastructure, extensive research and development, and rapid regulatory approvals.

Psoriatic arthritis is a chronic autoimmune inflammatory condition affecting the joints and skin and is frequently associated with psoriasis. Rising disease prevalence, increasing awareness, improved diagnosis, growing healthcare expenditure, and the introduction of innovative biologic therapies are supporting the expansion of the psoriatic arthritis treatment market.

Market Definition and Scope

The psoriatic arthritis treatment market includes pharmaceutical therapies used to manage joint inflammation, pain, skin symptoms, and disease progression. Treatment options include non-steroidal anti-inflammatory drugs (NSAIDs), non-biologic DMARDs, biologic DMARDs, and other therapies.

The market also covers treatment delivered through different administration routes, particularly oral and parenteral methods, along with distribution through hospital pharmacies, retail pharmacies, online pharmacies, and other channels. Increasing adoption of targeted biological treatments and biosimilars is further broadening the market landscape.

Market Dynamics

Drivers

The rising prevalence of psoriatic arthritis is a major factor driving market growth. Aging populations, stressful lifestyles, increasing psoriasis prevalence, longer life expectancy, and improved disease identification are contributing to a growing patient pool. The strong association between psoriasis and psoriatic arthritis is also increasing demand for effective treatment options.

Another important driver is the strong pipeline of innovative biologic drugs. Pharmaceutical companies are investing in targeted therapies designed to provide improved clinical outcomes. New product approvals and strategic collaborations are encouraging treatment innovation and increasing access to advanced therapies.

Trends

The growing penetration of biologic drugs is a prominent market trend. Traditional treatments have increasingly been complemented by targeted biologic and biosimilar therapies that address specific inflammatory pathways. Greater investment in research, clinical trials, and advanced treatment approaches is expected to strengthen biologic adoption.

The expansion of online pharmacies and telehealth services is another emerging trend, improving patient access to prescriptions and long-term treatment management.

Restraints

The high cost of biologic therapies remains a major restraint, particularly in developing countries where healthcare expenditure and reimbursement coverage may be limited. Adverse effects, delayed diagnosis, treatment-management gaps, stringent regulatory requirements, and patent expirations can also influence market growth.

Impact of COVID-19

The COVID-19 pandemic affected conventional healthcare access because patients requiring regular consultations faced restrictions and reduced hospital visits. However, the growing use of telehealth and online pharmacy services helped patients obtain consultations, prescriptions, and medications remotely. Although concerns existed regarding immunosuppressive therapies, healthcare providers continued to manage PsA patients through alternative care models, limiting the pandemic's long-term impact on the market.

Segmentation Analysis

By drug class, the market is divided into NSAIDs, non-biologic DMARDs, biologic DMARDs, and others. Biologic DMARDs are expected to dominate in 2026, supported by their effectiveness in controlling disease symptoms and increasing adoption of targeted therapies.

By route of administration, the market is categorized into oral and parenteral routes. The parenteral segment holds a leading position due to the widespread administration of biologic medicines through systemic and injectable methods.

By distribution channel, the market includes hospital pharmacies, retail pharmacies, online pharmacies, and others. Hospital pharmacies are expected to hold the largest share of 61.70% in 2025, supported by the use of systemic therapies and access to specialized healthcare professionals. Online pharmacies are expected to experience strong growth because of convenience and increasing internet penetration.

Regional Insights

North America led the psoriatic arthritis treatment market with a 43.78% share in 2025. The region benefits from high adoption of biologic treatments, substantial pharmaceutical R&D expenditure, advanced healthcare infrastructure, and rapid regulatory approvals in the U.S.

Europe is supported by improving access to advanced therapies and increasing healthcare expenditure. Asia Pacific is expected to experience the highest growth, driven by improving healthcare infrastructure, increasing healthcare spending, growing disease awareness, and expanding access to biologic therapies. Japan is projected to reach a market value of USD 659.7 million by 2025, while China is expected to witness strong growth. Latin America and the Middle East & Africa are emerging markets with increasing treatment opportunities.

Competitive Landscape

The market is relatively consolidated, with major pharmaceutical companies competing through biologic launches, clinical development, regulatory approvals, and strategic collaborations. Key players include F. Hoffmann-La Roche Ltd, Novartis AG, Amgen, Pfizer Inc., Johnson & Johnson Services, Eli Lilly and Company, AstraZeneca, Sanofi, Bristol-Myers Squibb, GlaxoSmithKline, and Bayer AG.

Key Industry Developments

In March 2019, AbbVie announced Japanese approval of SKYRIZI for several psoriasis-related indications, including psoriatic arthritis.

In October 2018, Novartis announced a European Commission label update for Cosentyx.

In December 2017, Pfizer received U.S. FDA approval for its infliximab biosimilar for several inflammatory conditions, including psoriatic arthritis.

Report Coverage

The report covers the global psoriatic arthritis treatment market size and forecast for 2025, 2026, and 2034, along with market dynamics, trends, growth drivers, restraints, COVID-19 impact, segmentation by drug class, route of administration and distribution channel, regional analysis, competitive landscape, leading companies, and major industry developments.

Conclusion

The global psoriatic arthritis treatment market, valued at USD 12.59 billion in 2025, is projected to reach USD 32.11 billion by 2034. Rising disease prevalence, expanding biologic treatment adoption, strong pharmaceutical pipelines, and increasing healthcare access will remain key growth factors. North America is expected to maintain its leading position, while Asia Pacific offers significant expansion opportunities. Continued development of targeted therapies, biosimilars, telehealth services, and convenient distribution channels is expected to strengthen the market outlook through 2034.

Unit Value (USD Billion)

Segmentation By Drug Class

  • Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
  • Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America (the U.S., and Canada)
  • Europe (the U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)
  • Latin America (Brazil, Mexico, and the Rest of Latin America)
  • The Middle East & Africa (South Africa, GCC and the Rest of the Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Psoriatic Arthritis for Key Countries/Region
  • 4.2. Recent Industry Developments Such as Partnerships, Mergers & Acquisitions, New Product Launches Etc.
  • 4.3. Pipeline Analysis for Key Companies
  • 4.4. Regulatory Framework by Key Countries
  • 4.5. Impact of COVID-19 on Psoriatic Arthritis Treatment Market

5. Global Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
    • 5.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs
    • 5.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Topical
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Drug Class
    • 6.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
    • 6.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs
    • 6.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs
  • 6.3. Market Analysis - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Topical
  • 6.4. Market Analysis - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online pharmacies
  • 6.5. Market Analysis - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Drug Class
    • 7.2.1. Non-steroidal Anti-inflammatory Drugs
    • 7.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs
    • 7.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs
  • 7.3. Market Analysis - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Topical
  • 7.4. Market Analysis - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online pharmacies
  • 7.5. Market Analysis - By Country/Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Drug Class
    • 8.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
    • 8.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs
    • 8.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs
  • 8.3. Market Analysis - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Topical
  • 8.4. Market Analysis - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online pharmacies
  • 8.5. Market Analysis - By Country/Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Drug Class
    • 9.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
    • 9.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs
    • 9.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs
  • 9.3. Market Analysis - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Topical
  • 9.4. Market Analysis - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online pharmacies
  • 9.5. Market Analysis - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Drug Class
    • 10.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
    • 10.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
    • 10.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
  • 10.3. Market Analysis - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Topical
  • 10.4. Market Analysis - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online pharmacies
  • 10.5. Market Analysis - By Country/Sub-region
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Company Profiles
    • 11.3.1. AbbVie Inc.
      • 11.3.1.1. Overview,
      • 11.3.1.2. Products,
      • 11.3.1.3. SWOT,
      • 11.3.1.4. Recent developments,
      • 11.3.1.5. strategies,
      • 11.3.1.6. financials (based on availability)
    • 11.3.2. Novartis AG
      • 11.3.2.1. Overview,
      • 11.3.2.2. Products,
      • 11.3.2.3. SWOT,
      • 11.3.2.4. Recent developments,
      • 11.3.2.5. strategies,
      • 11.3.2.6. financials (based on availability)
    • 11.3.3. Johnson & Johnson Services, Inc.
      • 11.3.3.1. Overview,
      • 11.3.3.2. Products,
      • 11.3.3.3. SWOT,
      • 11.3.3.4. Recent developments,
      • 11.3.3.5. strategies,
      • 11.3.3.6. financials (based on availability)
    • 11.3.4. Pfizer Inc.,
      • 11.3.4.1. Overview,
      • 11.3.4.2. Products,
      • 11.3.4.3. SWOT,
      • 11.3.4.4. Recent developments,
      • 11.3.4.5. strategies,
      • 11.3.4.6. financials (based on availability)
    • 11.3.5. LEO Pharma A/S
      • 11.3.5.1. Overview,
      • 11.3.5.2. Products,
      • 11.3.5.3. SWOT,
      • 11.3.5.4. Recent developments,
      • 11.3.5.5. strategies,
      • 11.3.5.6. financials (based on availability)
    • 11.3.6. Merck & Co., Inc.
      • 11.3.6.1. Overview,
      • 11.3.6.2. Products,
      • 11.3.6.3. SWOT,
      • 11.3.6.4. Recent developments,
      • 11.3.6.5. strategies,
      • 11.3.6.6. financials (based on availability)
    • 11.3.7. Amgen Inc.
      • 11.3.7.1. Overview,
      • 11.3.7.2. Products,
      • 11.3.7.3. SWOT,
      • 11.3.7.4. Recent developments,
      • 11.3.7.5. strategies,
      • 11.3.7.6. financials (based on availability)
    • 11.3.8. Eli Lilly and Company
      • 11.3.8.1. Overview,
      • 11.3.8.2. Products,
      • 11.3.8.3. SWOT,
      • 11.3.8.4. Recent developments,
      • 11.3.8.5. strategies,
      • 11.3.8.6. financials (based on availability)
    • 11.3.9. CELGENE CORPORATION
      • 11.3.9.1. Overview,
      • 11.3.9.2. Products,
      • 11.3.9.3. SWOT,
      • 11.3.9.4. Recent developments,
      • 11.3.9.5. strategies,
      • 11.3.9.6. financials (based on availability)
    • 11.3.10. UCB S.A.
      • 11.3.10.1. Overview,
      • 11.3.10.2. Products,
      • 11.3.10.3. SWOT,
      • 11.3.10.4. Recent developments,
      • 11.3.10.5. strategies,
      • 11.3.10.6. financials (based on availability)
    • 11.3.11. Sun Pharmaceutical Industries Ltd.
      • 11.3.11.1. Overview,
      • 11.3.11.2. Products,
      • 11.3.11.3. SWOT,
      • 11.3.11.4. Recent developments,
      • 11.3.11.5. strategies,
      • 11.3.11.6. financials (based on availability)
    • 11.3.12. Other prominent players
      • 11.3.12.1. Overview,
      • 11.3.12.2. Products,
      • 11.3.12.3. SWOT,
      • 11.3.12.4. Recent developments,
      • 11.3.12.5. strategies,
      • 11.3.12.6. financials (based on availability)

12. Strategic Recommendations

List of Tables

  • Table 1: Global Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Region, 2021-2034
  • Table 5: North America Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Drug Class, 2021-2034
  • Table 6: North America Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Drug Class, 2021-2034
  • Table 10: Europe Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 11: Europe Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Drug Class, 2021-2034
  • Table 14: Asia Pacific Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Asia Pacific Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Drug Class, 2021-2034
  • Table 18: Latin America Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Latin America Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Drug Class, 2021-2034
  • Table 22: Middle East & Africa Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Middle East & Africa Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Psoriatic Arthritis Treatment Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Psoriatic Arthritis Treatment Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
  • Figure 2: Global Psoriatic Arthritis Treatment Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Psoriatic Arthritis Treatment Market Forecast (USD Billion), by Non-Steroidal Anti-inflammatory Drugs (NSAIDS), 2021-2034
  • Figure 4: Global Psoriatic Arthritis Treatment Market Forecast (USD Billion), by Non-Biologic Disease Modifying Anti-Rheumatic Drugs, 2021-2034
  • Figure 5: Global Psoriatic Arthritis Treatment Market Forecast (USD Billion), by Biologic Disease Modifying Anti-Rheumatic Drugs, 2021-2034
  • Figure 6: Global Psoriatic Arthritis Treatment Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 7: Global Psoriatic Arthritis Treatment Market Forecast (USD Billion), by Oral, 2021-2034
  • Figure 8: Global Psoriatic Arthritis Treatment Market Forecast (USD Billion), by Parenteral, 2021-2034
  • Figure 9: Global Psoriatic Arthritis Treatment Market Forecast (USD Billion), by Topical, 2021-2034
  • Figure 10: Global Psoriatic Arthritis Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 11: Global Psoriatic Arthritis Treatment Market Forecast (USD Billion), by Hospital Pharmacies, 2021-2034
  • Figure 12: Global Psoriatic Arthritis Treatment Market Forecast (USD Billion), by Retail Pharmacies, 2021-2034
  • Figure 13: Global Psoriatic Arthritis Treatment Market Forecast (USD Billion), by Online Pharmacies, 2021-2034
  • Figure 14: Global Psoriatic Arthritis Treatment Market Value (USD Billion), by Region, 2025 & 2034
  • Figure 15: North America Psoriatic Arthritis Treatment Market Value (USD Billion), by Drug Class, 2025 & 2034
  • Figure 16: North America Psoriatic Arthritis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 17: North America Psoriatic Arthritis Treatment Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 18: North America Psoriatic Arthritis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 19: North America Psoriatic Arthritis Treatment Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 20: North America Psoriatic Arthritis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: North America Psoriatic Arthritis Treatment Market Value (USD Billion), By Country, 2025 & 2034
  • Figure 22: North America Psoriatic Arthritis Treatment Market Value Share (%), By Country, 2025
  • Figure 23: Europe Psoriatic Arthritis Treatment Market Value (USD Billion), by Drug Class, 2025 & 2034
  • Figure 24: Europe Psoriatic Arthritis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 25: Europe Psoriatic Arthritis Treatment Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 26: Europe Psoriatic Arthritis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 27: Europe Psoriatic Arthritis Treatment Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 28: Europe Psoriatic Arthritis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 29: Europe Psoriatic Arthritis Treatment Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 30: Europe Psoriatic Arthritis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 31: Asia Pacific Psoriatic Arthritis Treatment Market Value (USD Billion), by Drug Class, 2025 & 2034
  • Figure 32: Asia Pacific Psoriatic Arthritis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 33: Asia Pacific Psoriatic Arthritis Treatment Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 34: Asia Pacific Psoriatic Arthritis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 35: Asia Pacific Psoriatic Arthritis Treatment Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 36: Asia Pacific Psoriatic Arthritis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 37: Asia Pacific Psoriatic Arthritis Treatment Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 38: Asia Pacific Psoriatic Arthritis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 39: Latin America Psoriatic Arthritis Treatment Market Value (USD Billion), by Drug Class, 2025 & 2034
  • Figure 40: Latin America Psoriatic Arthritis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 41: Latin America Psoriatic Arthritis Treatment Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 42: Latin America Psoriatic Arthritis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Latin America Psoriatic Arthritis Treatment Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Psoriatic Arthritis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Psoriatic Arthritis Treatment Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Psoriatic Arthritis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Psoriatic Arthritis Treatment Market Value (USD Billion), by Drug Class, 2025 & 2034
  • Figure 48: Middle East & Africa Psoriatic Arthritis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 49: Middle East & Africa Psoriatic Arthritis Treatment Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 50: Middle East & Africa Psoriatic Arthritis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 51: Middle East & Africa Psoriatic Arthritis Treatment Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 52: Middle East & Africa Psoriatic Arthritis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 53: Middle East & Africa Psoriatic Arthritis Treatment Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 54: Middle East & Africa Psoriatic Arthritis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 55: Global Psoriatic Arthritis Treatment Market Share (%), By Company, 2025